On September 26, 2022 Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, reported that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will participate in the Cantor Fitzgerald Oncology & HemOnc Conference on September 28, 2022 at the Lotte New York Palace Hotel, New York, N.Y (Press release, Aravive, SEP 26, 2022, View Source [SID1234621423]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. McIntyre will participate in a panel discussion titled "Companies with Key Catalysts Over the Next 12-18 Months" on Wednesday, September 28, at 10:40 am ET.